Apollo, RMS REGROW bring cell therapy treatment for orthopedic patients

They will offer two new regenerative medicine cell therapy products- Ossron and Chondron

Apollo Hospitals has partnered with RMS REGROW to offer two new Regenerative Medicine Cell Therapy products- Ossron and Chondron for bone and cartilage problems, respectively. The two products will address clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee. In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India. Ossron and Chondron are innovative proprietary and patented technology which has been developed for both the products following the regulatory guidelines.

Reportedly, Apollo Hospitals will create a platform for orthopaedic doctors to practice Regenerative Medicine efficiently by conducting live surgical workshops, CME’s for doctors and conferences (national and international).

Commenting on the launch Yash Sanghavi, Founder and CEO of RMS REGROW, “We are delighted to partner with a leader like Apollo Hospitals which offers RMS REGROW unprecedented opportunity to reach patients pan India. It has taken 8 years of dedicated effort and innovative research to develop the two revolutionary products that will change the modalities for bone and cartilage treatment in India. Since last 70 years, only a handful of New Chemical Entities (NCE) have been developed in India, which demonstrates a dearth of innovator drugs and new medical technologies to address a large market of bone and joint disorders.”